Everything drug pricing and policy, every day
And a spate of stories about how MFN might impact pricing and access overseas
And evidence that the “biosimilar void” has been exaggerated
And new AAM data shows expanding savings from generics and biosimilars
And unpacking Trump administration claims about whether anyone is seeing MFN prices
And more evidence that we’re in for a record-breaking spike in healthcare costs
And clear your schedules this afternoon for the latest White House drug pricing fun
